Medicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.

(SOURCE) https://www.cnn.com/2022/04/07/politics/alzheimers-drug-aduhelm-medicare-clinical-trial/index.html